Delving into the Latest Updates on Chongqing Ruien Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

AChE(Acetylcholinesterase)	1

以重庆锐恩医药有限公司研制的多巴丝肼片（规格：0.25 g）为受试制剂，以持证商为上海罗氏制药有限公司的多巴丝肼片（商品名：美多芭®，规格：0.25 g）为参比制剂，考察两制剂在餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

The dopamine tablets (specification: 0.25 g) developed by Chongqing Ruien Pharmaceutical Co., Ltd. were used as the test preparation, and the dopamine tablets (trade name: Madopar®, specification: 0.25 g) produced by Shanghai Roche Pharmaceuticals Co., Ltd. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after a single dose in the postprandial state were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date-

Sponsor / Collaborator

Chongqing Ruien Pharmaceutical Co., Ltd.

CTR20240902 / CompletedNot Applicable

多巴丝肼片（0.25 g）人体生物等效性研究

[Translation] Study on the bioequivalence of dopamine tablets (0.25 g) in healthy volunteers

以重庆锐恩医药有限公司研制的多巴丝肼片（规格：0.25 g）为受试制剂，以持证商为上海罗氏制药有限公司的多巴丝肼片（商品名：美多芭®，规格：0.25 g）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

The dopamine tablets (specification: 0.25 g) developed by Chongqing Ruien Pharmaceutical Co., Ltd. were used as the test preparation, and the dopamine tablets (trade name: Madopar®, specification: 0.25 g) produced by Shanghai Roche Pharmaceuticals Co., Ltd. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations were investigated after single administration in the fasting and postprandial states to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date08 May 2024

Sponsor / Collaborator

Chongqing Ruien Pharmaceutical Co., Ltd.

100 Clinical Results associated with Chongqing Ruien Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Chongqing Ruien Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Chongqing Ruien Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Chongqing Ruien Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data